靶向白介素-2增强Pluvicto™的体内抗癌活性
本研究在新型PSMA表达模型HT-1080.hPSMA中评估Pluvicto™([177Lu]Lu-PSMA-617)与肿瘤靶向白介素-2药物L19-IL2联合的体内抗癌活性。结果显示联合方案在所有动物中实现治愈性持久缓解,且仅联合组在耐受剂量下表现出强效抗癌活性,蛋白组学提示L19-IL2增强免疫激活。作者认为低放射性剂量Pluvicto™的疗效可被L19-IL2有效增强,值得进一步临床探索。
要点
- 新型HT-1080.hPSMA模型显示Pluvicto™高选择性且持久的肿瘤摄取。
- Pluvicto™联合L19-IL2在所有荷瘤小鼠中实现治愈性持久缓解。
- 仅联合方案在耐受剂量下表现出强效体内抗癌活性。
核心结论
- 低放射性剂量Pluvicto™的治疗疗效可通过与L19-IL2联合得到有效增强。
- 作者认为该新型联合模式值得进一步临床探索。
研究设计与样本
- 研究建立并验证了新型PSMA表达模型HT-1080.hPSMA,用于Pluvicto™饱和与肿瘤滞留研究及L19-IL2联合治疗研究。
- 对单用Pluvicto™或联合免疫细胞因子治疗后的肿瘤样本进行蛋白组学实验以补充机制理解。
主要发现
- 在新型HT-1080.hPSMA模型中观察到Pluvicto™高选择性且持久的肿瘤摄取。
- HT-1080.hPSMA荷瘤小鼠治疗研究显示,Pluvicto™联合L19-IL2在所有动物中实现治愈性持久缓解。
- 仅联合方案在受治动物耐受的剂量下表现出强效体内抗癌活性。
- 蛋白组学提示L19-IL2增强了经Pluvicto™预处理动物的免疫系统激活。
局限性
- 作者结论指出该发现值得进一步临床探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pluvicto™ ([177Lu]Lu-PSMA-617), a radioligand therapeutic targeting prostate-specific membrane antigen (PSMA), has been recently approved for the treatment of metastatic castration-resistant prostate cancer (mCRPR). The drug suffers from salivary gland and kidney uptake that prevents its dose escalation to potentially curative doses. In this work, we sought to potentiate the in vivo anti-cancer activity of Pluvicto™ by combining it with L19-IL2, a clinical-stage investigational medicinal product based on tumor-targeted interleukin-2. METHODS: We established a new PSMA-expressing model (HT-1080.hPSMA) and validated it using a fluoresceine analogue of PSMA-617 (compound 1). The HT-1080.hPSMA model was used to study the saturation and tumor retention of Pluvicto™ (compound 2) and to run combination therapy studies with L19-IL2. To complement our understanding of the mechanism of action of this novel combination, we conducted proteomics experiments on tumor samples after therapy with Pluvicto™ alone or in combination with the immunocytokine. RESULTS: High, selective, and long-lived tumor uptake was observed for Pluvicto™ (2) in the novel HT-1080.hPSMA model. Therapy studies in HT-1080.hPSMA tumor-bearing mice revealed that the combination of Pluvicto™ (2) plus L19-IL2 mediated curative and durable responses in all animals. Potent in vivo anti-cancer activity was observed solely for the combination modality, at doses that were well tolerated by treated animals. Proteomics studies indicated that L19-IL2 boosts the activation of the immune system in animals pre-treated with Pluvicto™. CONCLUSION: The therapeutic efficacy of Pluvicto™ at low radioactive doses can be effectively enhanced by the combination with L19-IL2. Our findings warrant further clinical exploration of this novel combination modality.
引用
- Georgiev T, Principi L, Galbiati A, et al. Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto™. Eur J Nucl Med Mol Imaging. 2024. PMID: 38563883. doi:10.1007/s00259-024-06705-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。